Reply

On behalf of our co-authors, we appreciate the interest of Macaluso et al1 regarding our study, "Low Risk of Pneumonia From Pneumocystis jirovecii Infection in Patients With Inflammatory Bowel Disease Receiving Immune Suppression,"2 and agree with their comment regarding the lack of consensus on which patients should receive primary prophylaxis against Pneumocystis jirovecii pneumonia (PJP). We also agree with their suggestion that PJP prophylaxis be considered in inflammatory bowel disease (IBD) patients treated with a calcineurin inhibitor and we also believe, as noted in our article, that patients on triple immunosuppression should be considered at higher risk.

http://bit.ly/2tbszQd